个体化算法预测急性溃疡性结肠炎静脉糖皮质激素失败风险
基于682例急性溃疡性结肠炎连续就诊数据,用弹性网络模型筛选变量,构建含或不含内镜变量的ROR评分,并在181例和82例队列中验证。部分与完整ROR评分在主要验证队列的AUC分别为0.76和0.78,可在内镜评估前后识别激素无应答高风险患者。
要点
- 部分ROR评分纳入口服激素、排便频率≥6/24h、白蛋白、CRP≥12 mg/mL和log10CRP。
- 完整ROR评分在部分评分变量基础上增加Mayo内镜亚评分和病变范围。
- 主要验证队列中部分与完整ROR评分的AUC分别为0.76和0.78。
核心结论
- 这些实用的个体化ROR评分可在内镜评估前后识别糖皮质激素无应答高风险个体。
- ROR评分有潜力挑战常规急性UC治疗范式,识别可能从早期挽救治疗或相关临床试验中获益的患者。
研究设计与样本
- 分析682例急性UC连续就诊数据,基于419例最早就诊(1996-2017年)用AIC弹性网络模型筛选变量。
- 用逻辑回归构建含或不含内镜变量的两种风险评分算法。
- 在181例(2018-2022年)和82例(2015-2022年)急性UC就诊的独立队列中验证风险评分。
主要发现
- 部分ROR评分纳入入院时口服糖皮质激素治疗、排便频率≥6/24 h、白蛋白、CRP≥12 mg/mL和log10CRP。
- 完整ROR评分纳入相同变量并增加Mayo内镜亚评分和病变范围。
- 主要验证队列中部分ROR评分AUC为0.76(95% CI:0.69-0.83),完整ROR评分AUC为0.78(95% CI:0.71-0.85)。
关键数值与推荐
- 部分ROR评分包含:口服糖皮质激素治疗、排便频率≥6/24 h、白蛋白、CRP≥12 mg/mL、log10CRP。
- 完整ROR评分包含:上述变量加Mayo内镜亚评分和病变范围。
- 主要验证队列AUC:部分ROR评分0.76(95% CI:0.69-0.83),完整ROR评分0.78(95% CI:0.71-0.85)。
临床怎么用
- ROR评分可在内镜评估前后识别糖皮质激素无应答高风险患者。
- ROR评分有潜力识别可能从早期挽救治疗或相关临床试验中获益的患者。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An episode of acute ulcerative colitis (UC) represents an important watershed moment in a patient's disease course. AIMS: To derive a personalised algorithm for identifying patients at high risk of corticosteroid non-response from variables available at hospital presentation using a large prospectively collected acute UC patient database and machine learning-based techniques. METHODS: We analysed data from 682 consecutive presentations of acute UC. We used an Akaike information criterion-based elastic net model to select variables based on the 419 earliest presentations of acute UC (1996-2017). We constructed two risk-scoring algorithms, with and without utilising additional endoscopic variables, using logistic regression models. We validated these risk scores on separate cohorts of 181 (2018-2022) and 82 (2015-2022) acute UC presentations. RESULTS: The partial risk of rescue (ROR) score included the admission indices of oral corticosteroid treatment, bowel frequency ≥6/24 h, albumin, CRP ≥12 mg/mL and log10CRP. The full ROR score incorporates the same variables with the addition of the Mayo endoscopic subscore and disease extent. The AUCs in the main validation cohort were 0.76 (95% CI: 0.69-0.83) and 0.78 (95% CI: 0.71-0.85) for the partial and full ROR scores, respectively. CONCLUSIONS: These pragmatic personalised risk scores (available at www.severecolitis.com) have comparably strong performance characteristics and usability enabling the identification of individuals at high risk of corticosteroid non-response before or after endoscopic assessment. The ROR scores have the potential to challenge conventional acute UC treatment paradigms by identifying patients who may benefit from early rescue therapy or participation in relevant clinical trials.
引用
- Croft A, Okano S, Hartel G, et al. A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis. Aliment Pharmacol Ther. 2024. PMID: 39110549. doi:10.1111/apt.18190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。